eXoZymes (NASDAQ:EXOZ) Trading Up 5.5% – Here’s Why

eXoZymes Inc. (NASDAQ:EXOZ)’s stock price shot up 5.5% on Tuesday . The stock traded as high as $11.25 and last traded at $11.25. 3,006 shares changed hands during trading, a decline of 17% from the average session volume of 3,609 shares. The stock had previously closed at $10.66.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of eXoZymes in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, eXoZymes has an average rating of “Sell”.

eXoZymes Price Performance

The company has a quick ratio of 4.53, a current ratio of 4.53 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average price is $12.21 and its 200 day moving average price is $12.26. The firm has a market cap of $94.50 million, a price-to-earnings ratio of -14.61 and a beta of 2.36.

eXoZymes (NASDAQ:EXOZ) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share (EPS) for the quarter.

About eXoZymes

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.